$61.3 M

OBLN Mkt cap, 20-Sep-2018

$4.1 M

Obalon Therapeutics Revenue Q2, 2018
Obalon Therapeutics Gross profit (Q2, 2018)1.6 M
Obalon Therapeutics Gross profit margin (Q2, 2018), %38.7%
Obalon Therapeutics Net income (Q2, 2018)-21.9 M
Obalon Therapeutics EBIT (Q2, 2018)-21.7 M
Obalon Therapeutics Cash, 30-Jun-201824.2 M

Obalon Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

9.9 m

Cost of goods sold

2.8 m4.8 m

Gross profit

(2.8 m)5.1 m

Gross profit Margin, %

51%

R&D expense

9.9 m10.6 m

General and administrative expense

10.2 m28.8 m

Operating expense total

20.1 m39.5 m

EBIT

(19.5 m)(34.4 m)

EBIT margin, %

(347%)

Interest expense

477 k135 k

Net Income

(20.5 m)(34.8 m)

Quarterly

USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

773 k1.5 m2 m1.3 m4.1 m

Cost of goods sold

644 k823 k990 k769 k2.5 m

Gross profit

129 k649 k973 k577 k1.6 m

Gross profit Margin, %

17%44%50%43%39%

R&D expense

2.2 m2.4 m2.8 m2.6 m6 m

General and administrative expense

2.4 m5.9 m5.9 m10 m17.3 m

Operating expense total

4.6 m8.3 m8.6 m12.6 m23.2 m

EBIT

(4.5 m)(7.7 m)(7.6 m)(12.1 m)(21.7 m)

EBIT margin, %

(576%)(522%)(389%)(897%)(531%)

Interest expense

135 k54 k35 k37 k94 k

Net Income

(5.3 m)(7.7 m)(7.7 m)(12.1 m)(21.9 m)

Obalon Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

73 m21.1 m

Accounts Receivable

2.9 m4.2 m

Inventories

827 k1.4 m

Current Assets

78.1 m51.8 m

PP&E

717 k1.3 m

Total Assets

78.8 m53.1 m

Accounts Payable

595 k1.3 m

Current Liabilities

4.6 m10 m

Non-Current Liabilities

8 m

Total Liabilities

14.5 m18 m

Additional Paid-in Capital

140.9 m146.5 m

Retained Earnings

(76.6 m)(111.4 m)

Total Equity

64.3 m35.1 m

Financial Leverage

1.2 x1.5 x

Quarterly

USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

2.3 m41.7 m5.8 m33.5 m24.2 m

Accounts Receivable

1 m1.8 m

Inventories

438 k928 k747 k1.9 m1.8 m

Current Assets

18 m69.7 m63.9 m39.1 m31 m

PP&E

535 k903 k1 m1.4 m1.5 m

Total Assets

18.5 m70.6 m65 m40.5 m32.5 m

Accounts Payable

1.1 m823 k697 k2.3 m1.4 m

Current Liabilities

5.2 m3.6 m4.8 m9.1 m10.4 m

Non-Current Liabilities

9.9 m7 m6 m

Total Liabilities

15.1 m13.5 m14.8 m16.1 m16.4 m

Additional Paid-in Capital

2 m141.4 m142.3 m147.9 m149.3 m

Retained Earnings

(69.1 m)(84.4 m)(92.1 m)(123.5 m)(133.3 m)

Total Equity

57.1 m50.2 m24.4 m16.1 m

Financial Leverage

1.2 x1.3 x1.7 x2 x

Obalon Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(20.5 m)(34.8 m)

Depreciation and Amortization

192 k330 k

Accounts Receivable

(4.2 m)

Inventories

(464 k)(591 k)

Accounts Payable

46 k624 k

Cash From Operating Activities

(19.4 m)(30.6 m)

Purchases of PP&E

(352 k)(1 m)

Cash From Investing Activities

6.2 m(21.9 m)

Cash From Financing Activities

82.8 m613 k

Interest Paid

527 k562 k

Income Taxes Paid

2 k

Quarterly

USDQ3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(5.3 m)(7.7 m)(12.1 m)(21.9 m)

Depreciation and Amortization

129 k276 k

Accounts Receivable

1 m1.7 m1.2 m

Inventories

438 k928 k(449 k)(424 k)

Accounts Payable

1.1 m823 k1.1 m275 k

Cash From Operating Activities

(10.6 m)(18.7 m)

Purchases of PP&E

(358 k)(657 k)

Cash From Investing Activities

22.9 m21.6 m

Cash From Financing Activities

28 k179 k

Interest Paid

149 k307 k

Obalon Therapeutics Ratios

USDY, 2018

Financial Leverage

2 x
Report incorrect company information